Edition:
United Kingdom

NanoCarrier says basic agreement on international joint development of NC-6004 to treat head and neck cancer


Tuesday, 15 May 2018 

May 15 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says it entered into an agreement with the NC-6004 out-licensee, Orient Europharma Co Ltd <<<4120.TWO>>>, aimed at the Asian region, to integrate clinical development of NC-6004 for the treatment of head and neck cancer .Says two entities will conclude a basic agreement for additional licensing and joint development of NC-6004 in regions such as Europe and the United States. 

Company Quote

429.0
-1.0 -0.23%
19 Apr 2019